95 related articles for article (PubMed ID: 11512151)
1. Factors determining cellular mechanisms of resistance to antimitotic drugs.
Cabral F
Drug Resist Updat; 2001 Feb; 4(1):3-8. PubMed ID: 11512151
[TBL] [Abstract][Full Text] [Related]
2. Microtubule alterations and resistance to tubulin-binding agents (review).
Drukman S; Kavallaris M
Int J Oncol; 2002 Sep; 21(3):621-8. PubMed ID: 12168109
[TBL] [Abstract][Full Text] [Related]
3. Mutations at leucine 215 of beta-tubulin affect paclitaxel sensitivity by two distinct mechanisms.
Wang Y; Yin S; Blade K; Cooper G; Menick DR; Cabral F
Biochemistry; 2006 Jan; 45(1):185-94. PubMed ID: 16388594
[TBL] [Abstract][Full Text] [Related]
4. Cross-resistance to the synthetic retinoid CD437 in a paclitaxel-resistant human ovarian carcinoma cell line is independent of the overexpression of retinoic acid receptor-gamma.
Kumar A; Soprano DR; Parekh HK
Cancer Res; 2001 Oct; 61(20):7552-5. PubMed ID: 11606393
[TBL] [Abstract][Full Text] [Related]
5. Microtubule active agents: beyond the taxane frontier.
Morris PG; Fornier MN
Clin Cancer Res; 2008 Nov; 14(22):7167-72. PubMed ID: 19010832
[TBL] [Abstract][Full Text] [Related]
6. Tubulin and microtubules as targets for anticancer drugs.
Hadfield JA; Ducki S; Hirst N; McGown AT
Prog Cell Cycle Res; 2003; 5():309-25. PubMed ID: 14593726
[TBL] [Abstract][Full Text] [Related]
7. Antiangiogenic and antitumoral activity of phenyl-3-(2-chloroethyl)ureas: a class of soft alkylating agents disrupting microtubules that are unaffected by cell adhesion-mediated drug resistance.
Petitclerc E; Deschesnes RG; Côté MF; Marquis C; Janvier R; Lacroix J; Miot-Noirault E; Legault J; Mounetou E; Madelmont JC; C -Gaudreault R
Cancer Res; 2004 Jul; 64(13):4654-63. PubMed ID: 15231678
[TBL] [Abstract][Full Text] [Related]
8. Expression of class III beta-tubulin reduces microtubule assembly and confers resistance to paclitaxel.
Hari M; Yang H; Zeng C; Canizales M; Cabral F
Cell Motil Cytoskeleton; 2003 Sep; 56(1):45-56. PubMed ID: 12905530
[TBL] [Abstract][Full Text] [Related]
9. Microtubules: a dynamic target in cancer therapy.
Pasquier E; Kavallaris M
IUBMB Life; 2008 Mar; 60(3):165-70. PubMed ID: 18380008
[TBL] [Abstract][Full Text] [Related]
10. Anticancer therapy with novel tubulin-interacting drugs.
Kavallaris M; Verrills NM; Hill BT
Drug Resist Updat; 2001 Dec; 4(6):392-401. PubMed ID: 12030786
[TBL] [Abstract][Full Text] [Related]
11. Expression of beta-tubulin isotypes in human ovarian carcinoma xenografts and in a sub-panel of human cancer cell lines from the NCI-Anticancer Drug Screen: correlation with sensitivity to microtubule active agents.
Nicoletti MI; Valoti G; Giannakakou P; Zhan Z; Kim JH; Lucchini V; Landoni F; Mayo JG; Giavazzi R; Fojo T
Clin Cancer Res; 2001 Sep; 7(9):2912-22. PubMed ID: 11555610
[TBL] [Abstract][Full Text] [Related]
12. Alterations in gamma-actin and tubulin-targeted drug resistance in childhood leukemia.
Verrills NM; Po'uha ST; Liu ML; Liaw TY; Larsen MR; Ivery MT; Marshall GM; Gunning PW; Kavallaris M
J Natl Cancer Inst; 2006 Oct; 98(19):1363-74. PubMed ID: 17018783
[TBL] [Abstract][Full Text] [Related]
13. Microtubule assembly dynamics: an attractive target for anticancer drugs.
Singh P; Rathinasamy K; Mohan R; Panda D
IUBMB Life; 2008 Jun; 60(6):368-75. PubMed ID: 18384115
[TBL] [Abstract][Full Text] [Related]
14. Biochemical genetic analysis of indanocine resistance in human leukemia.
Hua XH; Genini D; Gussio R; Tawatao R; Shih H; Kipps TJ; Carson DA; Leoni LM
Cancer Res; 2001 Oct; 61(19):7248-54. PubMed ID: 11585762
[TBL] [Abstract][Full Text] [Related]
15. Epothilones: mechanism of action and biologic activity.
Goodin S; Kane MP; Rubin EH
J Clin Oncol; 2004 May; 22(10):2015-25. PubMed ID: 15143095
[TBL] [Abstract][Full Text] [Related]
16. Salvinal, a novel microtubule inhibitor isolated from Salvia miltiorrhizae Bunge (Danshen), with antimitotic activity in multidrug-sensitive and -resistant human tumor cells.
Chang JY; Chang CY; Kuo CC; Chen LT; Wein YS; Kuo YH
Mol Pharmacol; 2004 Jan; 65(1):77-84. PubMed ID: 14722239
[TBL] [Abstract][Full Text] [Related]
17. Modulation of endogenous beta-tubulin isotype expression as a result of human beta(III)cDNA transfection into prostate carcinoma cells.
Ranganathan S; McCauley RA; Dexter DW; Hudes GR
Br J Cancer; 2001 Sep; 85(5):735-40. PubMed ID: 11531260
[TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetic profile of the microtubule stabilizer patupilone in tumor-bearing rodents and comparison of anti-cancer activity with other MTS in vitro and in vivo.
O'Reilly T; Wartmann M; Brueggen J; Allegrini PR; Floersheimer A; Maira M; McSheehy PM
Cancer Chemother Pharmacol; 2008 Nov; 62(6):1045-54. PubMed ID: 18301895
[TBL] [Abstract][Full Text] [Related]
19. Pseudolaric acid B, a novel microtubule-destabilizing agent that circumvents multidrug resistance phenotype and exhibits antitumor activity in vivo.
Wong VK; Chiu P; Chung SS; Chow LM; Zhao YZ; Yang BB; Ko BC
Clin Cancer Res; 2005 Aug; 11(16):6002-11. PubMed ID: 16115945
[TBL] [Abstract][Full Text] [Related]
20. BPR0L075, a novel synthetic indole compound with antimitotic activity in human cancer cells, exerts effective antitumoral activity in vivo.
Kuo CC; Hsieh HP; Pan WY; Chen CP; Liou JP; Lee SJ; Chang YL; Chen LT; Chen CT; Chang JY
Cancer Res; 2004 Jul; 64(13):4621-8. PubMed ID: 15231674
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
